Lumenis presents the first and only IPL FDA-approved for the management of dry eye disease. OptiLight uses Lumenis’ patented Optimal Pulse Technology (OPT™) for a safe, precise, and effective treatment, clinically supported by over 40 clinical studies. This light-based therapy offers your patients an effective solution to a frustrating and persistent problem, and a timely opportunity for you to elevate your practice. With the huge market for DED treatments still largely unanswered, there’s never been a better time to introduce OptiLight into your practice.

As patients’ demand and interest in dry eye disease continues to soar, existing treatments remain largely ineffective. As these treatments mostly address the symptoms, but not the underlying condition and require daily intake, patients are left frustrated and in pain. A Gallup poll found a whopping 82% of patients wished a more effective treatment for DED was available, with another study reporting that merely 36% of patients strongly believe that the treatment they received was effective.

OptiLight is the first and only light based treatment for dry eye disease. It utilizes Lumenis’ patented Optimal Pulse Technology (OPT™) and built-in clinically validated treatment protocols to provide an effective and safe treatment that finally breaks the dry eye vicious cycle of inflammation. Thanks to the patented OPT™ handpiece, the treatment is easily customizable to fit every curve and outline of the delicate treatment area. It is intuitive, easy to use, and requires only minimal training and setup.

Each treatment session takes only 10-15 minutes (including prep time), so you can easily integrate it into your workflow. With over 20 clinical studies demonstrating its safety and effectiveness, Lumenis’ OptiLight is a transformative, must-have tool in your dry eye armamentarium.